CONNEXT is a spin-off company of Korea Institute of Industrial Technology (KITECH), a Korean government funded
research institute, offering highly purified recombinant proteins in a smart device for tissue engineering,
cell isolation and primary cell research field.
Founded in 2017, Connext is a Korean clinical-stage biotechnology company spun-off from a
government-funded research institute. Connext aims to improve quality of life by rapidly delivering
innovative medicines and technologies to patients. Based on its current portfolio, TLR5 agonist and
collagenase, Connext is expanding indications to cover a wide range of diseases in the areas of
oncology, dermatology and chronic wound care. To achieve this, Connext is focused on finding
opportunities to connect and collaborate with partners globally.